Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 552Neoplasms 502Carcinoma, Non-Small-Cell Lung 419Prostatic Neoplasms 326Colorectal Neoplasms 310Lung Neoplasms 280Neoplasm Metastasis 233Leukemia, Myeloid, Acute 222Ovarian Neoplasms 205Pancreatic Neoplasms 195Multiple Myeloma 186Recurrence 141Squamous Cell Carcinoma of Head and Neck 140Brain Neoplasms 139Stomach Neoplasms 138Melanoma 132Carcinoma, Hepatocellular 130Endometrial Neoplasms 127Glioblastoma 124Triple Negative Breast Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Hematologic Neoplasms 102Head and Neck Neoplasms 100Urinary Bladder Neoplasms 98Carcinoma, Renal Cell 98Lymphoma 97Glioma 94Sarcoma 93Esophageal Neoplasms 90Uterine Cervical Neoplasms 88

Interventions

elacestrant 1RAD1901 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenosarcoma of the uterus × 90 days × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡